Delay of treatment change following objective progression on first-line erlotinib in EGFR-mutant lung cancer

BACKGROUND: Erlotinib is a highly active EGFR kinase inhibitor approved for first-line use in lung cancers harboring EGFR mutations. Anecdotal experience suggests this drug may provide continued disease control following objective progression of disease (PD), however this has not been systematically...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer
Auteurs principaux: Lo, Peter C., Dahlberg, Suzanne E., Nishino, Mizuki, Johnson, Bruce E., Sequist, Lecia V., Jackman, David M., Jänne, Pasi A, Oxnard, Geoffrey R.
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525718/
https://ncbi.nlm.nih.gov/pubmed/25876525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.29397
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires